Phosphoenix, an Amsterdam-based medtech startup, has closed a €1.3 million financing round to accelerate development of its neuroprosthetic system designed to restore functional vision for individuals living with profound blindness. The round was led by ROM InWest, with participation from TTT Medtech Fund (managed by 819 Capital), FIRST Fund (managed by BioGeneration Ventures), and Innovatiefonds Noord-Holland.
The company, founded in 2019, is developing a brain-implant neuroprosthesis that aims to enable sight restoration for patients with severe vision loss. The fresh capital injection will support critical preparations for the startup’s first-in-human clinical study, further refinement of the neurostimulation technology, and groundwork for an anticipated Series A financing round.
Advancing Toward Clinical Trials
The funding marks a significant milestone for Phosphoenix as it transitions from preclinical development toward human trials. According to Hans Brons, presumably a company leader, the investment represents validation of progress made to date. “This financing represents an important step towards bringing our technology into the clinic,” Brons stated. “The continued support of our existing investors, together with the commitment of ROM InWest, provides strong validation of the progress we have made and enables us to advance our first‑in‑human preparations while building towards our Series A financing.”
The move reflects growing investor confidence in the company’s approach to addressing blindness, a condition affecting millions worldwide. By focusing resources on clinical trial readiness, Phosphoenix is positioning itself to demonstrate the safety and efficacy of its neuroprosthetic platform in real-world medical settings.
Market Opportunity and Innovation
The neuroprosthetics sector has attracted increasing attention from venture capital and strategic investors seeking to develop transformative solutions for neurological conditions. Brain-implant technologies that restore sensory function represent a frontier in medical innovation, though they require substantial validation before widespread clinical adoption.
Phosphoenix’s focus on profound blindness addresses a patient population with limited existing treatment options. Successful development of a functional visual neuroprosthesis could provide meaningful improvements in quality of life and independence for affected individuals.
European Medtech Growth
The funding underscores the Netherlands’ position as a growing hub for medical technology innovation within Europe. Dutch venture investors and medtech-focused funds have demonstrated sustained interest in early-stage healthcare startups tackling complex neurological challenges.
This financing also reflects broader European trends in neurotechnology funding, where investors increasingly back companies developing brain-computer interfaces and neural restoration systems. The participation of specialized medtech funds such as TTT Medtech Fund and FIRST Fund indicates structured venture support for the sector at the preclinical and early clinical stages.
As Phosphoenix moves toward its first-in-human trial, the company joins a growing cohort of European neurotechnology ventures seeking to translate fundamental research into clinical applications that address unmet medical needs.